BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31939437)

  • 1. Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma.
    Song Z; Ye J; Wang Y; Li Y; Wang W
    J Cancer Res Ther; 2019; 15(7):1553-1560. PubMed ID: 31939437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma.
    Collettini F; Schreiber N; Schnapauff D; Denecke T; Wust P; Schott E; Hamm B; Gebauer B
    Strahlenther Onkol; 2015 May; 191(5):405-12. PubMed ID: 25404063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unresectable colorectal liver metastases: percutaneous ablation using CT-guided high-dose-rate brachytherapy (CT-HDBRT).
    Collettini F; Lutter A; Schnapauff D; Hildebrandt B; Puhl G; Denecke T; Wust P; Gebauer B
    Rofo; 2014 Jun; 186(6):606-12. PubMed ID: 24407711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival.
    Mohnike K; Wieners G; Schwartz F; Seidensticker M; Pech M; Ruehl R; Wust P; Lopez-Hänninen E; Gademann G; Peters N; Berg T; Malfertheiner P; Ricke J
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):172-9. PubMed ID: 20056348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of computed tomography-guided
    He C; Liu Y; Li Y; Yang L; Li YT; Li SL; Huang XQ
    J Cancer Res Ther; 2018; 14(4):754-759. PubMed ID: 29970648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours.
    Collettini F; Schnapauff D; Poellinger A; Denecke T; Schott E; Berg T; Wust P; Hamm B; Gebauer B
    Eur Radiol; 2012 May; 22(5):1101-9. PubMed ID: 22173693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short- to mid-term evaluation of CT-guided 125I brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma.
    Zhang FJ; Li CX; Zhang L; Wu PH; Jiao DC; Duan GF
    Cancer Biol Ther; 2009 Apr; 8(7):585-90. PubMed ID: 19276683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma.
    Walter F; Nierer L; Rottler M; Duque AS; Weingandt H; Well J; Shpani R; Landry G; Seidensticker M; Streitparth F; Ricke J; Belka C; Corradini S
    Radiat Oncol; 2021 May; 16(1):86. PubMed ID: 33957941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-125 Brachytherapy Can Prolong Progression-Free Survival of Patients with Locoregional Recurrence and/or Residual Hepatocellular Carcinoma After Radiofrequency Ablation.
    Chen L; Ying X; Zhang D; Lai L; Wu F; Tu J; Ji J
    Cancer Biother Radiopharm; 2021 Dec; 36(10):820-826. PubMed ID: 32551979
    [No Abstract]   [Full Text] [Related]  

  • 10. Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum.
    Collettini F; Singh A; Schnapauff D; Powerski MJ; Denecke T; Wust P; Hamm B; Gebauer B
    Eur J Radiol; 2013 Oct; 82(10):e509-14. PubMed ID: 23791521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma.
    Qiu Z; Yu C; Qiu X; Li Q; Li J; Chen Z; Chang S; Zhang S; Fan G; Wang S
    Acad Radiol; 2023 Sep; 30 Suppl 1():S53-S60. PubMed ID: 36882354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Experience with CT-Guided High-Dose-Rate Brachytherapy in the Multimodality Treatment of Neuroendocrine Tumor Liver Metastases.
    Schippers AC; Collettini F; Steffen IG; Wieners G; Denecke T; Pavel M; Wust P; Gebauer B
    J Vasc Interv Radiol; 2017 May; 28(5):672-682. PubMed ID: 27645463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer.
    Wieners G; Schippers AC; Collettini F; Schnapauff D; Hamm B; Wust P; Riess H; Gebauer B
    Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):530-8. PubMed ID: 26459730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
    Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT-guided brachytherapy as salvage therapy for intrahepatic recurrence of HCC after surgical resection.
    Schnapauff D; Collettini F; Hartwig K; Wieners G; Chopra S; Hamm B; Gebauer B
    Anticancer Res; 2015 Jan; 35(1):319-23. PubMed ID: 25550566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of
    Xiang Z; Bai M; Li G; Zou B; Zhong Z; Gao F; Wu C; Huang M; Zhang F
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1907-1916. PubMed ID: 31161374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2 Study of Image-Guided Proton Therapy for Operable or Ablation-Treatable Primary Hepatocellular Carcinoma.
    Iwata H; Ogino H; Hattori Y; Nakajima K; Nomura K; Hashimoto S; Hayashi K; Toshito T; Sasaki S; Mizoe JE; Shibamoto Y
    Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):117-126. PubMed ID: 33798564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.